A pediatric B lineage leukemia with coincident MYC and MLL translocations.
Translocations are key oncogenic events, and many rearrangements are characteristic for a specific malignancy. We present here a case of phenotypic precursor-B acute lymphoblastic leukemia (ALL), subsequently found to have both MYC and MLL translocations. Owing to the potential prognostic impact of these translocations, a novel treatment strategy was applied which merged precursor-B ALL, Burkitt-ALL, and "MLL-adapted" rationales. With the advent of expanding diagnostic panels and molecular therapeutic options, use of such adapted therapies for individualized treatment will undoubtedly continue to increase as we move toward pharmacogenomic-based approaches.
Meeker
Nathan D
ND
Department of Pediatrics, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA. natemeeker@hotmail.com
Cherry
Athena M
AM
Bangs
Charles D
CD
Frazer
John Kimble
JK
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002675:Child, Preschool; D003520:Cyclophosphamide / Q000008:administration & dosage; D003561:Cytarabine / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D005434:Flow Cytometry; D011495:Histone-Lysine N-Methyltransferase; D006801:Humans; D008297:Male; D008727:Methotrexate / Q000008:administration & dosage; D051788:Myeloid-Lymphoid Leukemia Protein / Q000235:genetics*; D015452:Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / Q000188:drug therapy* / Q000235:genetics*; D011241:Prednisone / Q000008:administration & dosage; D016271:Proto-Oncogene Proteins c-myc / Q000235:genetics*; D014178:Translocation, Genetic; D014750:Vincristine / Q000008:administration & dosage
C497422:KMT2A protein, human; C489427:MYC protein, human; D016271:Proto-Oncogene Proteins c-myc; D003561:Cytarabine; D051788:Myeloid-Lymphoid Leukemia Protein; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011495:Histone-Lysine N-Methyltransferase; D011241:Prednisone; D008727:Methotrexate